ORAGENICS INC
For the period ended Dec 31, 2024. Filed Mar 14, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 14, 2025
OGEN$0.35+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONSOLIDATED STATEMENTS OF OPERATIONS
| For the Year Ended December 31, | |||
|---|---|---|---|
| 2024 · 2023 | |||
| Grant revenue | $ | - | $37,653 |
| Operating expenses: | |||
| Research and development | 4,114,434 | 15,490,604 | |
| General and administrative | 6,444,381 | 5,451,952 | |
| Total operating expenses | 10,558,815 | 20,942,556 | |
| Loss from operations | (10,558,815) | (20,904,903) | |
| Other income (expense): | |||
| Interest income | 45,897 | 210,394 | |
| Interest expense | (29,828) | (30,591) | |
| Miscellaneous income | - | 69,363 | |
| Foreign currency exchange, net | (25,172) | - | |
| Total other income (expense), net | (9,103) | 249,166 | |
| Loss before income taxes | (10,567,918) | (20,655,737) | |
| Income tax benefit | - | - | |
| Net loss | $(10,567,918) | $(20,655,737) | |
| Basic and diluted net loss per share | $(1.60) | $(9.18) | |
| Shares used to compute basic and diluted net loss per share | 6,621,934 | 2,249,694 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.